Olsalazine

Last updated
Olsalazine
Olsalazine Structure.svg
Clinical data
Trade names Dipentum
AHFS/Drugs.com Monograph
MedlinePlus a601088
License data
Pregnancy
category
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Pharmacokinetic data
Protein binding 99%
Elimination half-life 0.9 hours
Identifiers
  • 5,5'-diazenediyldi(2-hydroxybenzoic acid)
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.116.494 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C14H10N2O6
Molar mass 302.242 g·mol−1
3D model (JSmol)
  • O=C(O)c1cc(ccc1O)/N=N/c2cc(C(O)=O)c(O)cc2
  • InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)/b16-15+ Yes check.svgY
  • Key:QQBDLJCYGRGAKP-FOCLMDBBSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Olsalazine is an anti-inflammatory medication used in the treatment of ulcerative colitis. [2] [3] It is sold under the brand name Dipentum. [4]

Contents

Olsalazine itself is a prodrug of mesalazine (5-aminosalicyclic acid or 5-ASA) and is not absorbed in the small intestine. Instead it continues through to the colon where it is cleaved into two molecules of 5-ASA by azoreductases produced by colonic bacteria. Olsalazine thus exerts its anti-inflammatory effect by its colonic breakdown into 5-ASA which inhibits cyclooxygenase and lipoxygenase thereby reducing prostaglandin and leukotriene production. [4]

History

Olsalazine gained Food and Drug Administration (FDA) approval in 1990.

Supply

The drug is supplied by UCB Pharma.

Research

In 2006 the Australian biotech company Giaconda received a European patent for a combination therapy for treating constipation-predominant irritable bowel syndrome that uses olsalazine and the anti-gout drug colchicine, for trials the following year. [5]

References

  1. ↑ "Olsalazine (Dipentum) Use During Pregnancy". Drugs.com. 6 September 2019. Retrieved 9 October 2020.
  2. ↑ "Olsalazine--a further choice in ulcerative colitis". Drug and Therapeutics Bulletin. 28 (15): 57–8. July 1990. doi:10.1136/dtb.28.15.57. PMID   2131213. S2CID   7178709.
  3. ↑ Wadworth AN, Fitton A (April 1991). "Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease". Drugs. 41 (4): 647–64. doi:10.2165/00003495-199141040-00009. PMID   1711964. S2CID   243654426.
  4. 1 2 "Olsalazine Sodium 250 mg Capsules - Summary of Product Characteristics (SmPC) - (emc)". www.medicines.org.uk. Retrieved 9 January 2021.
  5. ↑ "Giaconda gets European patent for drug". The Sydney Morning Herald. 28 December 2006. Retrieved 16 January 2021.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.